Videos

Jocelyn Mueller, a patient with HER2-positive breast cancer, explains how she received her diagnosis.

The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer.

Julie Fisher, MD, gives a brief overview of HER2-positive breast cancer and the tests available for diagnosis.

Stephen Liu, MD, and Danielle Hicks illustrate how molecular testing impacts targeted therapy selection in non-small cell lung cancer.

Key opinion leaders explain how to discuss biomarker testing with non-small cell lung cancer patients, as well as the common questions they field.

People living with metastatic breast cancer share highlights of their personal self-care strategies.

Julie Larson, LCSW, and a panel of women living with metastatic breast discuss the impact of the disease on mental health and resources to consider as a patient.

Knowing the type, phase and eligibility criteria is key in reading cancer research.

The rationale for waiting on results of molecular testing prior to initiating treatment for patients with non-small cell lung cancer.

The difference between tissue and liquid biopsies used in non-small cell lung cancer, and what patients should know about their results and treatment decision-making.

Stephen Liu, MD, and Danielle Hicks describe the purpose and the importance of biomarker testing in non-small cell lung cancer.

Shared insight on novel treatments for non-small cell lung cancer and how patients should advocate for themselves and seek best available care.

Allison Collins shares her experience undergoing a break from therapy after she responded well to treatment for non-small cell lung cancer.

The panel discusses the social impact of metastatic breast cancer diagnosis on the relationships in their lives.

Shirley Mertz, MA, JD, Lisa Laudico, and Sheila McGlown share their stories of being diagnosed with metastatic breast cancer.

After undergoing treatment for leukemia in the middle of his career as a radiation oncologist, Dr. Curtis Mack noticed that he became a more empathetic and patient doctor.

What patients need to know about molecular testing and treatment decisions in non-small cell lung cancer.

Reactions to low rates of molecular testing for patients with non-small cell lung cancer in community settings.

A brief discussion on the importance of enrolling in clinical trials and when that may be an option in non-small cell lung cancer.

An in-depth explanation of biomarkers in non-small cell lung cancer, particularly how they can affect the disease and treatment options.

Allison Collins reflects on the genetic testing she underwent after receiving a non-small cell lung cancer diagnosis and describes the treatment options presented to her at that time.

CURE®’s first episode of our new cooking show is finally here! We’ll give step-by-step instructions for three delicious recipes to support readers through every step of the cancer process.

View the full CURE® Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami on demand.

Dr. Vamsidhar Velcheti provides an expert’s insight on the testing and staging that must be performed during a diagnosis of non-small cell lung cancer.

Drs. Charu Aggarwal and Hossein Borghaei comment on the importance of having predictive and prognostic biomarkers in non-small cell lung cancer and highlight their approaches to testing patients prior to initiating therapy.

Considerations for the emotional impact of a lung cancer diagnosis and how patients can be supported during their treatment journey.

Approaches that can help lung oncologists discuss symptoms and risk factors of non-small cell lung cancer with patients and their loved ones.

Allison Collins describes her diagnosis with KRAS-positive non-small cell lung cancer and the symptoms that led her to seek medical attention.

Ms. Addario, lung cancer survivor, encourages patients with non-small cell lung cancer to use all the resources and tools that are available to them.

Challenges surrounding the screening of high-risk patients for lung cancer in the community.